Is adagrasib included in medical insurance?

Adagrasib is a targeted therapy that belongs to a class of drugs known as KRAS G12C inhibitors. It is being developed to treat advanced or metastatic non-small cell lung cancer (NSCLC) and other solid tumors with KRAS G12C mutations.

Since adagrasib is not yet available on the domestic market, patients are currently unable to purchase it directly domestically and must obtain it through overseas channels. The price of the original Adagrasibu drug produced in the United States is extremely high, reaching more than 180,000 yuan, making it unaffordable for ordinary families. But what is gratifying is that foreign generic drugs have recently come out. Among them, the generic drug of adagrasibu launched by Lucius Pharmaceuticals in Laos is relatively affordable, priced at about four to five thousand yuan per box, and its pharmaceutical ingredients are basically the same as the original drug.

KRAS gene mutations are one of the most common mutations in many cancers, including NSCLC, colorectal cancer, and pancreatic cancer. In the KRAS G12C mutation, a specific location in the KRAS gene is changed, causing abnormal proliferation and growth of cancer cells. Since KRAS gene mutations are critical to the occurrence and development of tumors, therapeutic strategies targeting this mutation have become one of the hot topics of research.

The mechanism of action of adagrasib is to inhibit the proliferation and growth of cancer cells by inhibiting the activity ofKRAS G12C mutant. It blocks abnormal cell signaling pathways by binding to specific parts of the KRAS protein, thereby interfering with the survival and proliferation mechanisms of cancer cells. This makes adagrasib a promising new drug for the treatment of tumors harboring the KRAS G12C mutation.

Clinical trials have shown that adagrasib exhibits significant anti-tumor activity in some patients with advanced cancer. Although further research is still needed to determine its long-term efficacy and safety, adagrasiib provides a new treatment option for patients who once lacked effective treatments.

However, like all medications, adagrasib may cause a range of adverse effects. Common adverse reactions include fatigue, digestive problems (such as nausea, vomiting, diarrhea), skin reactions, muscle cramps, high blood pressure, headaches, etc. When using adagrasib, patients and physicians should closely monitor possible side effects and take appropriate measures as needed.